Gå direkt till huvudinnehållet

Systemisk svampinfektion

Senast uppdaterad: Publicerad:

  1. Patterson TF. Advances and challenges in management of invasive mycoses. Lancet 2005; 366: 1013-25. PubMed  
  2. Patterson TF, Kirkpatrick WR, White M et al. Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. Medicine (Baltimore) 2000; 79: 250-60. PubMed  
  3. Lin SJ, Schranz J and Teutsch SM. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis 2001; 32: 358-66. PubMed  
  4. Pappas PG, Rex JH, Lee J et al. A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin Infect Dis 2003; 37: 634-43. PubMed  
  5. McNeil MM, Nash SL, Hajjeh RA et al. Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997. Clin Infect Dis 2001; 33: 641-7. PubMed  
  6. Groll AH, Shah PM, Mentzel C, Schneider M, Just-Nuebling G and Huebner K. Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. J Infect 1996; 33: 23-32. PubMed  
  7. Marr KA, Seidel K, White TC and Bowden RA. Candidemia in allogeneic blood and marrow transplant recipients: Evolution of risk factors after the adoption of prophylactic fluconazole. J Infect Dis 2000; 181: 309-16. PubMed  
  8. Profylax och behandling av invasiv svampinfektion vid hematologisk sjukdom samt efter stamcellstransplantation – uppdaterad rekommendation. Läkemedelsverket 2011 www.lakemedelsverket.se  
  9. Gudlaugsson O, Gillespie S, Lee K et al. Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis 2003; 37: 1172-7. PubMed  
  10. Viudes A, Peman J, Canton E, Ubeda P, Lopez-Ribot JL and Gobernado M. Candidemia at a tertiary-care hospital: epidemiology, treatment, clinical outcome and risk factors for death. Eur J Clin Microbiol Infect Dis 2002; 21: 767-74. PubMed  
  11. Ostrosky-Zeichner L. New approaches to the risk of Candida in the intensive care unit. Curr Opin Infect Dis 2003; 16: 533-7. PubMed  
  12. Ramage G, Wickes BL and Lopez-Ribot JL. Biofilms of Candida albicans and their associated resistance to antifungal agents. Am Clin Lab 2001; 20: 42-4. PubMed  
  13. Martin GS, Mannino DM, Eaton S and Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003; 348: 1546-54. New England Journal of Medicine  
  14. Mora-Duarte J, Betts R, Rotstein C et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002; 347: 2020-9. New England Journal of Medicine  
  15. Eggiman P, Garbino J and Pittet D. Epidemiology of Candida species infections in critically ill non-immunosuppressed patients. Lancet Infect Dis 2003; 3: 685-702. PubMed  
  16. Pfaller MA, Diekema DJ, Jones RN et al. International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobial surveillance program. J Clin Microbiol 2001; 39: 3254-9. PubMed  
  17. Abi-Said D, Anaissie E, Uzun O, Raad I, Pinzcowski H and Vartivarian S. The epidemiology of hematogenous candidiasis caused by different Candida species. Clin Infect Dis 1997; 24: 1122-8. PubMed  
  18. Denning DW. Early diagnosis of invasive aspergillosis. Lancet 2000; 355: 423-4. PubMed  
  19. Perfect JR, Cox GM, Lee JY et al. The impact of culture isolation of Aspergillus species: a hospital-based survey of aspergillosis. Clin Infect Dis 2001; 33: 1824-33. PubMed  
  20. Warris A, Bjorneklett A and Gaustad P. Invasive pulmonary aspergillosis associated with infliximab therapy. N Engl J Med 2001; 344: 1099-1100. New England Journal of Medicine  
  21. Marty FM, Lee SJ, Fahey MM et al. Infliximab use in patients with severe graft-versus-host disease and other emerging risk factors of non-Candida invasive fungal infections in allogeneic hematopoietic stem cell transplant recipients: a cohort study. Blood 2003; 102: 2768-76. Blood  
  22. Walsh TJ, Pappas P, Winston DJ et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002; 346: 225-34. New England Journal of Medicine  
  23. Marr KA, Carter RA, Boeckh M, Martin P and Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 2002; 100: 4358-66. Blood  
  24. Hajjeh RA and Warnock DW. Counterpoint: invasive aspergillosis and the environment-rethinking our approach to prevention. Clin Infect Dis 2001; 33: 1549-52. PubMed  
  25. Anaissie EJ and Costa SF. Nosocomial aspergillosis is waterborne. Clin Infect Dis 2001; 33: 1546-8. PubMed  
  26. Wheat J. Histoplasma capsulatum antigen detection: Comparison of the performance characteristics of a new inhibition immunoassay to those of an established antibody sandwich immunoassay. J Clin Microbiol 1999; 37: 2387. PubMed  
  27. Maertens J, Verhaegen J, Lagrou K, Van Eldere J and Boogaerts M. Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation. Blood 2001; 97: 1604-10. Blood  
  28. Swanink CMA, Meis JFGM, Rijs AJMM, Donnelly JP and Verweij PE. Specificity of a sandwich enzyme-linked immunosorbent assay for detecting Aspergillus galactomannan. J Clin Microbiol 1997; 35: 257-60. PubMed  
  29. Pinel C, Fricker-Hidalgo H, Lebeau B et al. Detection of circulating Aspergillus fumigatus galactomannan: value and limits of the Platelia test for diagnosing invasive aspergillosis. J Clin Microbiol 2003; 41: 2184-6. PubMed  
  30. Ascioglu S, Rex JH, de Pauw B et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: An international consensus. Clin Infect Dis 2002; 34: 7-14. PubMed  
  31. Caillot D, Couaillier JF, Bernard A et al. Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia. J Clin Oncol 2001; 19: 253-9. PubMed  
  32. Rodriguez LJ et al. Update on invasive candidiasis. Adv Pharmacol 1997; 37: 349. PubMed  
  33. Stevens DA, Kan VL, Judson MA et al. Practice guidelines for diseases caused by Aspergillus. Clin Infect Dis 2000; 30: 696-709. PubMed  
  34. Bates DW, Su L, Yu DT et al. Mortality and costs of acute renal failure associated with amphotericin B therapy. Clin Infect Dis 2001; 32: 686-93. PubMed  
  35. Wingard JR, Kubilis P, Lee L et al. Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. Clin Infect Dis 1999; 29: 1402-7. PubMed  
  36. Barrett JP, Vardulaki KA, Conlon C et al. A systematic review of the antifungal effectiveness and tolerability of amphotericin B formulations. Clin Ther 2003; 25: 1295-320. PubMed  
  37. Denning DW. Echinocandin antifungal drugs. Lancet 2003; 362: 1142-51. PubMed  
  38. Steinbach WJ and Stevens DA. Review of newer antifungal and immunomodulatory strategies for invasive aspergillosis. Clin Infect Dis 2003; 37 (suppl 3): S157-S187.
  39. Kontoyiannis DP, Hachem R, Lewis RE et al. Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies. Cancer 2003; 98: 292-9. PubMed  
  40. Aliff TB, Maslak PG, Jurcic JG et al. Refractory Aspergillus pneumonia in patients with acute leukemia: successful therapy with combination caspofungin and liposomal amphotericin. Cancer 2003; 97: 1025-32. PubMed  
  41. Saag MS, Graybill RJ, Larsen RA et al. Practice guidelines for the management of cryptococcal disease. Clin Infect Dis 2000; 30: 710-8. PubMed  
  • Bertil Christensson, professor och överläkare, Infektionskliniken, Skånes universitetssjukhus

Tidigare sakkunniga

  • Terje Johannessen, professor i allmänmedicin, Institutt for samfunnsmedisinske fag, Norges teknisk-naturvitenskapelige universitet, Trondheim